Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
2.940
-0.090 (-2.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
May 26, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022
May 25, 2022
Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of...
Via
Benzinga
Expert Ratings For Amylyx Pharmaceuticals
April 01, 2022
Within the last quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) has observed the following analyst ratings:
Via
Benzinga
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
May 16, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
May 12, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
May 05, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
FDA Panel Votes Down For Amylyx's ALS Drug, Further Fading Its Hope For Regulatory Success
March 31, 2022
An advisory committee of the
Via
Benzinga
Amylyx Pharma Stock Hinges On This FDA Action — Here's What To Know
March 30, 2022
Amylyx is facing an FDA advisory committee Wednesday that will vote on its ALS drug.
Via
Investor's Business Daily
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
Amylyx Shares Plummet On Skeptical FDA Adcomm Docs On ALS Drug
March 28, 2022
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
April 02, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest
April 01, 2022
One analyst says Reata only has a 50% chance in a neurodegenerative disease.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022
April 01, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
March 31, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
March 30, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
March 30, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Amylyx Pharmaceuticals Stock Trading Halted Today
March 30, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
50 Biggest Movers From Yesterday
March 29, 2022
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in...
Via
Benzinga
Mid-Day Market Update: Crude Oil Dips 8%; Plantronics Shares Spike Higher
March 28, 2022
U.S. stocks traded mixed midway through trading, with the Dow dropping 175 points on Monday.
Via
Benzinga
35 Stocks Moving In Monday's Mid-Day Session
March 28, 2022
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) jumped 57.1% to $1.96 following reports regarding potential future investments from AMC CEO, Adam Aron....
Via
Benzinga
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
March 28, 2022
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week.
Via
Investor's Business Daily
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
March 28, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Mid-Morning Market Update: Markets Mixed; SAIC Profit Tops Views
March 28, 2022
U.S. stocks traded mixed this morning, with the Dow dropping around 100 points on Monday.
Via
Benzinga
Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO
March 26, 2022
Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market...
Via
Talk Markets
Stocks That Hit 52-Week Lows On Monday
March 28, 2022
On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
IPO Stock Amylyx Pharmaceuticals Broke Down — But Just Wait For Its Encore
March 25, 2022
Here's why a former breakdown stock, Amylyx, has run up for two consecutive days.
Via
Investor's Business Daily
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.